Empowered Funds LLC Takes $220,000 Position in Insulet Co. (NASDAQ:PODD)

Empowered Funds LLC acquired a new position in shares of Insulet Co. (NASDAQ:PODD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 946 shares of the medical instruments supplier’s stock, valued at approximately $220,000.

A number of other institutional investors and hedge funds have also bought and sold shares of PODD. Blue Trust Inc. boosted its stake in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in Insulet during the 2nd quarter worth approximately $32,000. Venturi Wealth Management LLC grew its holdings in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares during the last quarter. UMB Bank n.a. increased its position in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the period. Finally, CVA Family Office LLC raised its stake in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the last quarter.

Insulet Stock Down 0.1 %

Shares of NASDAQ:PODD opened at $266.42 on Wednesday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40. The business’s 50 day simple moving average is $241.97 and its two-hundred day simple moving average is $211.65. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market cap of $18.69 billion, a P/E ratio of 45.62, a PEG ratio of 4.02 and a beta of 1.22.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PODD. Canaccord Genuity Group boosted their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. UBS Group increased their price target on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Barclays lifted their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Sanford C. Bernstein began coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Finally, Morgan Stanley boosted their target price on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.